



June 6, 2013

Pharmacy Announcement

Drug Use Review Board Notification for Changes Effective May 16, 2013

On July 26, 2012, the Nevada Drug Use Review (DUR) Board approved the following changes to Medicaid Services Manual (MSM) Chapter 1200 Prescribed Drugs, which were effective May 16, 2013:

- All products containing acetaminophen will be limited to 3,000 mg (3 gm) per day based on quantity submitted and day supply.
- Lyrica® (Pregabalin) will no longer require prior authorization.
- The following will require prior authorization:
 - Daliresp® (Roflumilast)
 - Xarelto® (Rivaroxaban)
 - Bydureon® (Exenatide), Victoza® (Liraglutide) and Byetta® (Exenatide)
 - Kalydeco (Ivacaftor)
 - Natroba® (Spinosad)
 - Brilinta® (Ticagrelor)
 - Xopenex® (Levalbuterol) HFA inhaler

Prior authorization forms can be found on this website on the [Pharmacy Forms](#) webpage. [MSM Chapter 1200](#) can be found on the DCHFP website.